- Akdeniz Tıp Dergisi
- Vol: 9 Issue: 2
- WHICH TREATMENT SHOULD BE SELECTED FOR THE OPTIMUM APPROACH TO PATIENTS WITH NON-SMALL CELL LUNG CAN...
WHICH TREATMENT SHOULD BE SELECTED FOR THE OPTIMUM APPROACH TO PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH DRIVER MUTATION? A CASE REPORT AND LITERATURE REVIEW
Authors : Onur Yazdan Balçik, Esin Oktay, Gizem Dönmez Yalçin
Pages : 226-230
Doi:10.53394/akd.996247
View : 10 | Download : 6
Publication Date : 2023-05-01
Article Type : Research Article
Abstract :We present a case of concomitant c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) and fusion in non small cell lung cancer (NSCLC) in a 59-year-old patient and review the treatment efficacy of co-mutations. The choice of the treatment and its effectiveness with rare co-mutations is a subject of considerable interest. This review will provide clues to the optimal treatment approach to NSCLC patients with more than one driver mutations. However, randomized studies are needed to clarify which patients with concurrent mutations may benefit from chemotherapy or related tki.Keywords : ALK, ROS, MUTASYON, AKCİĞER